Attorney's Docket No.: 07419-029001 / 00-228

Applicant: Gordon et al. Filed : January 18, 2000

Page

: 2

<u>AMENDMENT</u>

Please amend the application as follows:

In the claims:

Please cancel claims 11-13, 16, and 47-49, without prejudice.

Please replace claims 1-4, 9, 10, 14, 28, 29, 46, and 50 with amended claims 1-4, 9, 10, 14, 28, 29, 46, and 50 as follows:

- -- 1. (4x Amended) An isolated or recombinant nucleic acid consisting of a nucleic acid sequence having at least 75% sequence identity to SEQ ID NO:3, or its complement, wherein the nucleic acid selectively hybridizes to SEQ ID NO:3 or its complement.
- 2. (3x Amended) An isolated or recombinant nucleic acid fragment of a nucleic acid of claim 1, 4, or 45, wherein the nucleic acid fragment is 10 to 20 to 30 nucleotides and selectively hybridizes to SEQ ID NO:3 or its complement.
- 3. (4x Amended) An isolated or recombinant nucleic acid fragment of a nucleic acid of claim 1, 4, or 45, wherein the nucleic acid fragment is 30 nucleotides or more and selectively hybridizes to SEQ ID NO:3 or its complement.
- 4. (4x Amended) An isolated or recombinant nucleic acid consisting of a sequence as set forth in SEQ ID NO:3, or its complement.
- The nucleic acid of claim 1, 4, or 45, or fragments thereof 9. (3x Amended) that selective hybridize to SEQ ID NO:3, comprising a label.
- 10. (4x Amended) An isolated or recombinant nucleic acid fragment of claim 1, 4, or 45, wherein the nucleic acid fragment is between about 15 and about 200 residues

Applicant: Gordon et al. Serial No.: 09/484,577

Filed : January 18, 2000

Page : 3

in length; is between about 25 and about 100 residues in length; or is between about 35 and about 75 residues in length.

Attorney's Docket No.: 07419-029001 / 00-228

14. (4x Amended) A transformed cell comprising the nucleic acid of claim 1, 4, or 45, or fragments thereof that selectively hybridize to SEQ ID NO:3.

F8

- A kit for detecting the presence of nucleic acid sequences 28. (4x Amended) associated with GCA in a sample comprising at least one type of nucleic acid of claim 1, 4, or 45, wherein the nucleic acid selectively hybridizes to SEQ ID NO:3 or its complement.
- A kit for detecting the presence of nucleic acid sequences 29. (4x Amended) associated with GCA in a sample comprising at least one type of nucleic acid fragment of claim 2.
- 46. (2x Amended) A method for detecting the presence of SEQ ID NO:3 for diagnosing GCA comprising the following steps:
- providing a nucleic acid of claim 1, 4, or 45, or fragments thereof that (a) selectively hybridize to SEQ ID NO:3;
 - providing a tissue sample comprising nucleic acids; (b)
- contacting the nucleic acid with the nucleic acids in the sample under (c) hybridizing conditions; and
- detecting whether the nucleic acid hybridizes to a nucleic acid in the (d) sample, wherein the specific hybridization indicates the presence of SEQ ID NO:3 in the sample and is diagnostic for GCA.

50. (Amended) The method of claim 62, wherein the amplification is by polymerase chain reaction (PCR). --

Please add claims 51-62.

Attorney's Docket No.: 07419-029001 / 00-228

Applicant: Gordon et al. Serial No.: 09/484,577

Filed

: January 18, 2000

Page: 4

-- 51. The nucleic acid of claim 1, wherein the nucleic acid has a sequence having 80% identity to the sequence of SEQ ID NO:3 or its complement.

- 52. The nucleic acid of claim 1, wherein the nucleic acid has a sequence having 85% identity to the sequence of SEQ ID NO:3 or its complement.
- 53. The nucleic acid of claim 1, wherein the nucleic acid has a sequence having 90% identity to the sequence of SEQ ID NO:3 or its complement.
- 54. The nucleic acid of claim 1, wherein the nucleic acid has a sequence having 95% identity to the sequence of SEQ ID NO:3 or its complement.
- 55. The nucleic acid of claim 1, wherein the nucleic acid has a sequence having 98% identity to the sequence of SEQ ID NO:3 or its complement.
- 56. The nucleic acid of claim 1, 4, or 45, or fragments thereof that selectively hybridize to SEQ ID NO:3, wherein the nucleic acid is flanked by heterologous nucleotides.
- 57. The nucleic acid of claim 56, wherein the heterologous nucleotides comprise an expression vector.
 - 58. A transformed cell comprising the expression vector of claim 57.
- 59. A kit for detecting the presence of nucleic acid sequences associated with GCA in a sample comprising at least one type of nucleic acid fragment of claim 3.
- 60. A kit for detecting the presence of nucleic acid sequences associated with GCA in a sample comprising at least one type of nucleic acid fragment of claim 10.

Applicant: Gordon et al. Attorney's Docket No.: 07419-029001 / 00-228 Serial No.: 09/484,577

Filed : January 18, 2000

Page : 5

61. An array comprising the nucleic acid of claim 1, 4, or 45, or fragments thereof that selectively hybridize to SEQ ID NO:3.

62. A method for detecting the presence of SEQ ID NO:3 for diagnosing GCA comprising the following steps:

- providing at least two different nucleic acids of claim 1, 4, or 45, or fragments (a) thereof that selectively hybridize to SEQ ID NO:3 to be used as amplification primer pairs;
 - providing a tissue sample comprising nucleic acids; (b)
- contacting the nucleic acids with the nucleic acids in the sample under (c) amplification reaction conditions; and
- detecting whether the primer pair has amplified products, wherein amplified (d) products indicate the presence of SEQ ID NO:3 in the sample and is diagnostic for GCA. --

